^
    Back
    Association details:
    Biomarker:KRAS amplification
    Cancer:Pancreatic Cancer
    Drug:Mektovi (binimetinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Br J Cancer
    Title:

    KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

    Excerpt:
    Cell lines with a KRAS (V12) mutation and KRAS gains or loss (n=7) are ∼10 times more resistant than those having neither a KRAS (V12) mutation nor KRAS CNV (n=14).
    DOI:
    10.1038/bjc.2014.475